Rational Design of Cross-protective T cell Vaccines
- Funded by Wellcome Trust
- Total publications:0 publications
Grant number: 302473/Z/23/Z
Grant search
Key facts
Disease
COVID-19, UnspecifiedStart & end year
20242032Known Financial Commitments (USD)
$2,898,841.16Funder
Wellcome TrustPrincipal Investigator
Dr. Leo SwadlingResearch Location
United KingdomLead Research Institution
University College LondonResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen morphology, shedding & natural history
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Keywords: Vaccines, T-cells, Immunology, Virology, Cross-reactivity, Coronavirus, Machine Learning, Proactive Vaccinology, T-cell Receptor. The fundamental problem when designing vaccines for variable viruses is how to induce immunity that can recognise and protect against the breadth of globally circulating viral strains. T-cells have an inherent ability to cross-recognise a wide range of viral sequences because they recognise short linear peptides, in particular within essential conserved non-structural proteins. Challenging the immunological paradigm that T-cells alone cannot block infection, I recently demonstrated that pre-existing T-cells targeting the most conserved proteins across the coronavirus family, the replication-transcription complex (RTC), correlate with protection from detectable SARS-CoV-2 infection in exposed seronegative individuals (Swadling.Nature.2022). This suggests cross- species protection from infection by T-cells alone and that specificity is linked to protective efficacy. It is essential now to identify precisely which epitopes within the RTC are mediating this cross-protection so that we can: 1) integrate analysis of the viral sequence, TCR repertoire, and functional cross-reactivity at these epitopes to elucidate the fundamental rules underpinning T-cell cross-reactivity; 2) use these epitopes in pan-coronavirus vaccines. Ultimately, I will test the hypothesis that 'rational design of vaccines to induce cross-protective T-cell immunity will lead to effective infection blocking vaccines for variable viruses'.